secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000719135-22-000088
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q3 revenue down 23% YoY; cuts full-year 2022 guidance
------------------------------------------------------------------

- Total revenue $9.1M (-23% YoY); Advanced Energy revenue $7.1M (-31% YoY).
- Net loss $5.8M ($0.17/share) vs $4.2M loss in Q3 2021; Adjusted EBITDA loss $3.9M.
- Full-year 2022 revenue guidance cut to $44.8M-$47.9M from prior $51.0M-$56.4M.
- Company cites continued disruption from March FDA Safety Communication as primary headwind.
- OEM revenue grew 34% to $2.0M, partially offsetting Advanced Energy decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913522000088/0000719135-22-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913522000088/apyx-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000719135-22-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer